Skip to main content
Journal cover image

ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing.

Publication ,  Journal Article
Russo, AM; Desai, MY; Do, MM; Butler, J; Chung, MK; Epstein, AE; Guglin, ME; Levy, WC; Piccini, JP; Bhave, NM; Ambardekar, AV; Berg, NC ...
Published in: J Am Coll Cardiol
March 25, 2025

This appropriate use criteria (AUC) document is developed by the American College of Cardiology along with key specialty and subspecialty societies. It provides a comprehensive review of common clinical scenarios where implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy (CRT), cardiac contractility modulation, leadless pacing, and conduction system pacing therapies are frequently considered. The 335 clinical scenarios covered in this document address ICD indications including those related to secondary prevention, primary prevention, comorbidities, generator replacement at elective replacement indicator, dual-chamber, and totally subcutaneous ICDs, as well as device indications related to CRT, conduction system pacing, leadless pacing, cardiac contractility modulation, and ICD therapy in the setting of left ventricular assist devices (LVADs). The indications (clinical scenarios) were derived from common applications or anticipated uses, as well as from current clinical practice guidelines and results of studies examining device implantation. The indications in this document were developed by a multidisciplinary writing group and scored by a separate independent rating panel on a scale of 1 to 9 to designate care that is considered “Appropriate” (median 7 to 9), “May Be Appropriate” (median 4 to 6), and “Rarely Appropriate” (median 1 to 3). The final ratings reflect the median score of the 17 rating panel members. In general, Appropriate designations were assigned to scenarios for which clinical trial evidence and/or clinical experience was available that supported device implantation. In contrast, scenarios for which clinical trial evidence was limited or device implantation seemed reasonable for extenuating or practical reasons were categorized as May Be Appropriate. Scenarios for which there were data showing harm, or no data were available, and medical judgment deemed device therapy was illadvised were categorized as Rarely Appropriate. For example, comorbidities including reduced life expectancy related to noncardiac conditions or severe cognitive dysfunction would negatively impact appropriateness ratings. The appropriate use criteria for ICD, CRT, and pacing have the potential to enhance clinician decision making, healthcare delivery, and payment policy. Furthermore, recognition of clinical scenarios rated as May Be Appropriate facilitates the identification of areas where there may be gaps in evidence that would benefit from future research.

Duke Scholars

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

March 25, 2025

Volume

85

Issue

11

Start / End Page

1213 / 1285

Location

United States

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Russo, A. M., Desai, M. Y., Do, M. M., Butler, J., Chung, M. K., Epstein, A. E., … Zareba, K. M. (2025). ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing. J Am Coll Cardiol, 85(11), 1213–1285. https://doi.org/10.1016/j.jacc.2024.11.023
Russo, Andrea M., Milind Y. Desai, Monika M. Do, Javed Butler, Mina K. Chung, Andrew E. Epstein, Maya E. Guglin, et al. “ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing.J Am Coll Cardiol 85, no. 11 (March 25, 2025): 1213–85. https://doi.org/10.1016/j.jacc.2024.11.023.
Russo AM, Desai MY, Do MM, Butler J, Chung MK, Epstein AE, et al. ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing. J Am Coll Cardiol. 2025 Mar 25;85(11):1213–85.
Russo, Andrea M., et al. “ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing.J Am Coll Cardiol, vol. 85, no. 11, Mar. 2025, pp. 1213–85. Pubmed, doi:10.1016/j.jacc.2024.11.023.
Russo AM, Desai MY, Do MM, Butler J, Chung MK, Epstein AE, Guglin ME, Levy WC, Piccini JP, Bhave NM, Ambardekar AV, Berg NC, Bilchick KC, Dec GW, Gopinathannair R, Han JK, Klein L, Lampert RJ, Panjrath GS, Reeves RR, Yoerger Sanborn DM, Stevenson LW, Truong QA, Varosy PD, Villines TC, Volgman AS, Zareba KM. ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing. J Am Coll Cardiol. 2025 Mar 25;85(11):1213–1285.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

March 25, 2025

Volume

85

Issue

11

Start / End Page

1213 / 1285

Location

United States

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology